Diong Sui'un ücretlendirmesi LYC Healthcare Berhad'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-RM 19m
Jun 30 2024	n/a	n/a	-RM 20m
Mar 31 2024	RM 1m	RM 862k	-RM 19m
Dec 31 2023	n/a	n/a	-RM 17m
Sep 30 2023	n/a	n/a	-RM 17m
Jun 30 2023	n/a	n/a	-RM 17m
Mar 31 2023	RM 1m	RM 660k	-RM 19m
Dec 31 2022	n/a	n/a	-RM 12m
Sep 30 2022	n/a	n/a	-RM 12m
Jun 30 2022	n/a	n/a	-RM 11m
Mar 31 2022	RM 837k	RM 530k	-RM 9m
Dec 31 2021	n/a	n/a	-RM 11m
Sep 30 2021	n/a	n/a	-RM 12m
Jun 30 2021	n/a	n/a	-RM 12m
Mar 31 2021	RM 779k	RM 443k	-RM 12m
Dec 31 2020	n/a	n/a	-RM 14m
Sep 30 2020	n/a	n/a	-RM 12m
Jun 30 2020	n/a	n/a	-RM 11m
Mar 31 2020	RM 484k	RM 324k	-RM 10m
Dec 31 2019	n/a	n/a	-RM 8m
Sep 30 2019	n/a	n/a	-RM 8m
Jun 30 2019	n/a	n/a	-RM 8m
Mar 31 2019	RM 429k	RM 300k	-RM 8m
Dec 31 2018	n/a	n/a	-RM 7m
Sep 30 2018	n/a	n/a	-RM 6m
Jun 30 2018	n/a	n/a	-RM 4m
Mar 31 2018	RM 287k	RM 287k	-RM 3m

Tazminat ve Piyasa: Diong 'nin toplam tazminatı ($USD 265.02K ), MY pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 107.74K ).

Tazminat ve Kazançlar: Diong şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Diong Sui (69 yo)

7.3yrs

Görev süresi

RM 1,187,000

Tazminat

Mr. Diong Hoe Sui has been an Executive Director of LYC Healthcare Berhad (formerly known as Mexter Technology Berhad) since July 12, 2016. Mr. Sui served as Managing Director of Ralco Corporation Berhad (...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Diong Sui	MD, Group CEO & Executive Director	7.3yrs	RM 1.19m	Veri yok
Sook Chong	Chief Financial Officer	less than a year	Veri yok	Veri yok
Yan Lim	Chief Investment Officer & COO of Confinement Centres	no data	Veri yok	Veri yok
Lai Chow	Senior Group Accountant	2.2yrs	Veri yok	Veri yok
Siew Chong	Head of the ICT & Electronics Engineering Division	no data	Veri yok	Veri yok
Hoo Soh	Chief Executive Officer of Project Management Division	no data	Veri yok	Veri yok
Ying Chan	Executive Director & MD of LYC Medicare Singapore Limited	no data	Veri yok	Veri yok
Choon Meng Ting	Managing Director of T&T Medical Group Pte Ltd	no data	Veri yok	Veri yok
Ai Tan	Company Secretary	no data	Veri yok	Veri yok
Yuen Tai	Company Secretary	no data	Veri yok	Veri yok

2.2yrs

Ortalama Görev Süresi

55.5yo

Ortalama Yaş

Deneyimli Yönetim: LYC 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Diong Sui	MD, Group CEO & Executive Director	8.5yrs	RM 1.19m	Veri yok
Mohd bin Ahmad	Independent Non Executive Director	8.2yrs	RM 76.00k	Veri yok
Abdul bin Mohamad Zabidi	Independent Non-Executive Chairman	3.9yrs	RM 106.00k	Veri yok
Sin Kong	Independent Non Executive Director	less than a year	Veri yok	Veri yok
Muraly Daran	Independent Non-Executive Director	4.4yrs	RM 76.00k	Veri yok
Zuan Poh	Independent & Non Executive Director	1.7yrs	RM 62.00k	Veri yok

4.2yrs

Ortalama Görev Süresi

66.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: LYC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.2 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/02 07:40
Gün Sonu Hisse Fiyatı	2025/01/02 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

LYC Healthcare Berhad 1 Bu analistlerden 0, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Wei Soong	RHB Investment Bank

LYC Healthcare Berhad Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

LYC Healthcare Berhad Appoints Kong Sin Seng as Independent and Non Executive Chairman of Audit Committee

LYC Healthcare Berhad Approves Audit Committee Be Changed to Audit and Risk Management Committee, Effective September 28, 2024

Shareholders May Be More Conservative With LYC Healthcare Berhad's (KLSE:LYC) CEO Compensation For Now

LYC Healthcare Berhad, Annual General Meeting, Sep 27, 2024

Lyc Healthcare Berhad Appoints Chong Sook Peng as Chief Financial Officer

LYC Healthcare Berhad Announces Resignation of Mr. Cheah SEK Hon as Chief Financial Officer , Effective from 28 April 2024

Recent updates

New major risk - Share price stability

Second quarter 2025 earnings released: RM0.004 loss per share (vs RM0.007 loss in 2Q 2024)

Is LYC Healthcare Berhad (KLSE:LYC) Weighed On By Its Debt Load?

LYC Healthcare Berhad Appoints Kong Sin Seng as Independent and Non Executive Chairman of Audit Committee

Wong Chew Weng agreed to acquire an additional 55% stake in Elite Dental Team Sdn Bhd from LYC Healthcare Berhad (KLSE:LYC) for MYR 6.5 million.

LYC Healthcare Berhad Approves Audit Committee Be Changed to Audit and Risk Management Committee, Effective September 28, 2024

Shareholders May Be More Conservative With LYC Healthcare Berhad's (KLSE:LYC) CEO Compensation For Now

Take Care Before Diving Into The Deep End On LYC Healthcare Berhad (KLSE:LYC)

Full year 2024 earnings released: RM0.029 loss per share (vs RM0.035 loss in FY 2023)

LYC Healthcare Berhad, Annual General Meeting, Sep 27, 2024

Is LYC Healthcare Berhad (KLSE:LYC) Using Too Much Debt?

Full year 2024 earnings released: RM0.03 loss per share (vs RM0.035 loss in FY 2023)

New minor risk - Share price stability

LYC Healthcare Berhad (KLSE:LYC) Doing What It Can To Lift Shares

Lyc Healthcare Berhad Appoints Chong Sook Peng as Chief Financial Officer

Third quarter 2024 earnings released: RM0.006 loss per share (vs RM0.007 loss in 3Q 2023)

LYC Healthcare Berhad Announces Resignation of Mr. Cheah SEK Hon as Chief Financial Officer , Effective from 28 April 2024

LYC Healthcare Berhad Announces Resignation of Encik Ahmad Rafique Bin Mat Tahir as Chief Operating Officer, Effective 19 February.2024

Second quarter 2024 earnings released: RM0.006 loss per share (vs RM0.009 loss in 2Q 2023)

LYC Healthcare Berhad has filed a Follow-on Equity Offering in the amount of MYR 12.804571 million.

New minor risk - Share price stability

Does LYC Healthcare Berhad (KLSE:LYC) Have A Healthy Balance Sheet?

LYC Healthcare Berhad's (KLSE:LYC) CEO Compensation Is Looking A Bit Stretched At The Moment

Full year 2023 earnings released: RM0.035 loss per share (vs RM0.021 loss in FY 2022)

LYC Healthcare Berhad, Annual General Meeting, Sep 21, 2023

Is LYC Healthcare Berhad (KLSE:LYC) Using Too Much Debt?

Full year 2023 earnings released: RM0.035 loss per share (vs RM0.021 loss in FY 2022)

LYC Healthcare Berhad Appoints Poh Zuan Yin as Independent and Non Executive Member of Audit Committee

LYC Healthcare Berhad (KLSE:LYC) acquired 55% stake in Elite Dental Team Sdn Bhd from Kenneth Wong Pak Ken, Wong Chew Weng, Carmen Yuen Chia-Wen, Yee Xin Le and Sylvia Lim Sze Wei.

Is LYC Healthcare Berhad (KLSE:LYC) A Risky Investment?

Third quarter 2023 earnings released: RM0.007 loss per share (vs RM0.007 loss in 3Q 2022)

LYC Healthcare Berhad's (KLSE:LYC) Returns On Capital Are Heading Higher

Second quarter 2023 earnings released: RM0.009 loss per share (vs RM0.007 loss in 2Q 2022)

It's Unlikely That The CEO Of LYC Healthcare Berhad (KLSE:LYC) Will See A Huge Pay Rise This Year

Here's Why LYC Healthcare Berhad (KLSE:LYC) Is Weighed Down By Its Debt Load

LYC Healthcare Berhad announced a financing transaction

Full year 2022 earnings released: RM0.021 loss per share (vs RM0.033 loss in FY 2021)

LYC Healthcare Berhad, Annual General Meeting, Sep 22, 2022

LYC Healthcare Berhad (KLSE:LYC) entered into a conditional share sale agreement to acquire a 55% stake in Elite Dental Team Sdn Bhd from Kenneth Wong Pak Ken, Wong Chew Weng, Carmen Yuen Chia-Wen, Yee Xin Le and Sylvia Lim Sze Wei for MYR 5.5 million.

LYC Healthcare Berhad (KLSE:LYC) entered into a conditional share sale agreement to acquire a 55% stake in Elite Dental Team Sdn Bhd from Kenneth Wong Pak Ken, Wong Chew Weng, Carmen Yuen Chia-Wen, Yee Xin Le and Sylvia Lim Sze Wei for MYR 5.5 million.

LYC Healthcare Berhad Announces Appointment of Mr. Cheah SEK Hon as Chief Financial Officer

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investors Will Want LYC Healthcare Berhad's (KLSE:LYC) Growth In ROCE To Persist

LYC Healthcare Berhad (KLSE:LYC) agreed to acquire Tao Global Ventures Sdn Bhd from Dinesh A/L Kanasen and Sarahanna A/P Selvarajah for RMB 4 million.

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Does LYC Healthcare Berhad (KLSE:LYC) Have A Healthy Balance Sheet?

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2021 earnings released: RM0.033 loss per share (vs RM0.029 loss in FY 2020)

Is LYC Healthcare Berhad (KLSE:LYC) Using Too Much Debt?

Full year 2021 earnings released: RM0.032 loss per share (vs RM0.029 loss in FY 2020)

How Should Investors React To LYC Healthcare Berhad's (KLSE:LYC) CEO Pay?

Third quarter 2021 earnings released: RM0.013 loss per share (vs RM0.006 loss in 3Q 2020)

Non-Independent Non-Executive Director has left the company

LYC Healthcare Berhad Announces Resignation of Josephie Sui Sze Pin as Non Independent and Non Executive Member of Remuneration Committee

New 90-day low: RM0.25

New 90-day low: RM0.29

New 90-day low: RM0.30

New 90-day low: RM0.32

Second quarter 2021 earnings released: RM0.008 loss per share

LYC Healthcare Berhad (KLSE:LYC) acquired remaining 49% stake in LYC Cosmetic & Aesthetic Sdn Bhd from Xing Dao International Pte. Ltd for MYR 0.05 million.

New 90-day low: RM0.33

First quarter earnings released

First quarter earnings released

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi